Clinical application of selective renal artery embolization in treating kidney diseases
10.3760/cma.j.issn.1673-4904.2009.11.018
- VernacularTitle:选择性肾动脉造影栓塞术在肾脏疾病中的临床应用
- Author:
Jiaping WANG
;
Changxing KE
;
Yingchun LI
;
Shuguang YUAN
;
Dong YAN
;
Jiansong WANG
;
Yuyun TONG
;
Quansheng ZHU
- Publication Type:Journal Article
- Keywords:
Kidney neoplasms;
Wounds and injuries;
Angiography;
Embolization
- From:
Chinese Journal of Postgraduates of Medicine
2009;32(11):44-47
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical application of selective renal artery embolization (SRAE) for the treatment of kidney diseases. Methods Seventy-four cases of renal carcinomas, 11 cases of renal angiomyolipomas (RAML) and 72 cases of traumatic renal haemorrhages were first demonstrated by renal arteriography under Seldinger technique to ensure a site, range and neighbouring relation of lesions and then followed by percutaneous catheterized selective renal arterial embolization with embolic agents. Results The edema around the carcinomas and abscesses became obvious, and bleeding were reduced, which were convenient for operation after SRAE for the preoperative adjuvant treatment of renal carcinomas. The clinical symptoms were improved obviously in 9 eases with advanced renal carcinoma after palliative treatment. The tumour volumes of 11 RAML were decreased evidently by 15 %-65 % with the average of 42 %. The bleeding in 68 cases of traumatic renal haemorrhage were ceased completely in 1-4 days after embolism, 2 cases with serious renal fragmented injury and huge perirenal hematoma combined with shock received successful operation after SRAE, 2 cases bleeding again after SRAE were cured by the second SRAE. No severe complications occurred after embolization in all the patients. Conclusions As a minimal invasive technique,selective renal artery embolization is a safe, effective method with less complications and an adjuvant pre-op-erative therapy for renal carcinoma or a palliative treatment for advanced carcinoma and an effective treatment for RAML and traumatic renal haemorrhage.
